SynthesisFrontiers in public health2026
Changes in short-chain fatty acids across the glycemic spectrum: a systematic review and meta-analysis.
Synthesis in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Short-chain fatty acids (SCFAs) modulate insulin sensitivity, but evidence on their association with type 2 diabetes mellitus (T2DM) is inconsistent, possibly due to dynamic changes across the glycemic spectrum from normal glucose tolerance (NGT) to established T2DM. This systematic review characterizes stage-specific variation in SCFAs to assess their potential value as metabolic correlates of T2DM. Methods: PubMed, Web of Science, Embase, and the Cochrane Library were searched up to December 2025 for observational studies on SCFAs involving participants with NGT, prediabetes (pre-DM), or established T2DM. Continuous/binary outcomes were expressed as standardized mean differences (SMDs)/odds ratios (ORs) with 95% confidence intervals (CIs). Newcastle-Ottawa Scale (NOS) and Agency for Healthcare Research and Quality (AHRQ) criteria assessed study quality. Data were pooled using fixed-effects or random-effects models according to Results: 17 studies (7,371 participants) were included. Based on 6 studies, butyrate was significantly lower in T2DM than in NGT (SMD: -0.49, 95% CI [-0.96, -0.01]), and the finding was robust in sensitivity analyses, whereas the observed increase in valerate was not. No significant differences in SCFAs were found between pre-DM and NGT except for propionate (1 study). Single-study analyses using either SMD or OR indicated lower acetate levels in T2DM than in pre-DM. Fecal, but not circulating, acetate and butyrate were significantly lower in T2DM than in NGT, with a significant sample-type subgroup difference only for acetate. Conclusion: SCFA alterations were more evident in established T2DM than in pre-DM, with reduced butyrate emerging as the most consistent finding. Acetate showed a less consistent pattern, varying across glycemic comparisons and biological matrices. These findings highlight SCFAs as key metabolic correlates of T2DM and support further prospective and interventional research on their potential nutritional and metabolic relevance. Systematic review registration: https://www.crd.york.ac.uk/prospero/. The Systematic Review Registration PROSPERO (No. CRD420251245821).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.